ARPA-H, the advanced research agency under the U.S. Department of Health and Human Services, has announced a substantial investment of $62.7 million aimed at developing artificial intelligence technologies to enhance the treatment of heart failure. This initiative, named ADVOCATE, seeks to create partially autonomous AI systems that will be authorized by the FDA to assist in clinical decision-making, including evaluating symptom severity, prescribing medications, and ordering necessary laboratory tests.
On Wednesday, ARPA-H disclosed its first round of funding allocations to a group of health technology companies, including Atman Health, UpDoc, Tempus AI, and collaborative teams from prestigious institutions such as Stanford University and Duke University. The initial funding for the first year totals $33.7 million, with the potential for further financial adjustments based on project developments.
The implications of this funding are significant, particularly considering that approximately 6.7 million Americans living with heart failure often face challenges in accessing specialized care. By leveraging AI technologies, ARPA-H aims to bridge this treatment gap, especially in rural and underserved communities, potentially transforming the landscape of heart failure management.
Open the full market picture for your next decision →
